Edition:
United States

Dechra Pharmaceuticals PLC (DPH.L)

DPH.L on London Stock Exchange

2,976.00GBp
11:55am EDT
Change (% chg)

-2.00 (-0.07%)
Prev Close
2,978.00
Open
2,960.00
Day's High
2,990.00
Day's Low
2,956.00
Volume
190,475
Avg. Vol
236,205
52-wk High
3,032.00
52-wk Low
1,666.00

Latest Key Developments (Source: Significant Developments)

Dechra Pharmaceuticals Says HY Revenue Up 11 Pct
Monday, 26 Feb 2018 02:30am EST 

Feb 26 (Reuters) - Dechra Pharmaceuticals Plc ::SAYS REPORTED GROUP REVENUE FOR SIX MONTHS ENDED 31 DECEMBER 2017 INCREASED BY 11.2% AT CONSTANT EXCHANGE RATE.SAYS EUROPEAN PHARMACEUTICALS REVENUE GROWTH WAS 5.8% AT CONSTANT EXCHANGE RATE FOR SIX MONTHS ENDED 31 DECEMBER 2017.DECHRA PHARMACEUTICALS - NORTH AMERICAN PHARMACEUTICALS REVENUE GROWTH WAS 20.7% AT CONSTANT EXCHANGE RATE FOR SIX MONTHS ENDED 31 DECEMBER 2017.DECHRA PHARMACEUTICALS - ‍HY UNDERLYING OPERATING PROFIT GROWTH OF 22.3% AT CER (22.6% AT AER) WITH OPERATING MARGIN EXPANSION OF 220 BPS TO 24.6%​.‍HY UNDERLYING DILUTED EPS GROWTH OF 19.8% TO 37.58 PENCE​.HY ‍UNDERLYING PROFIT BEFORE TAXATION INCREASED BY 17.6% AT CER TO £44.3 MILLION​.‍DECLARE AN INTERIM DIVIDEND OF 7.33 PENCE PER SHARE​.‍CURRENT TRADING CONTINUES IN LINE WITH MANAGEMENT EXPECTATIONS​.  Full Article

Dechra Says ‍Trading In Line With Management Expectations
Tuesday, 9 Jan 2018 02:00am EST 

Jan 9 (Reuters) - Dechra Pharmaceuticals Plc ::‍TRADING IN PERIOD WAS STRONG AND IN LINE WITH MANAGEMENT EXPECTATIONS​.‍REPORTED GROUP REVENUE FOR PERIOD INCREASED BY C.10.5% AT CONSTANT EXCHANGE RATE (CER) (C.11.5% AT ACTUAL EXCHANGE RATE (AER))​.  Full Article

Dechra Pharmaceuticals ‍Q1 performance in line with management expectations
Friday, 20 Oct 2017 02:00am EDT 

Oct 20 (Reuters) - Dechra Pharmaceuticals Plc ::DECHRA PHARMACEUTICALS - ‍ PERFORMANCE IN Q1 OF FINANCIAL YEAR WAS IN LINE WITH MANAGEMENT EXPECTATIONS, WITH CONTINUED GROWTH ACROSS ALL OF ITS MARKETS​.  Full Article

Dechra says trading in line with management expectations
Thursday, 6 Jul 2017 02:00am EDT 

July 6 (Reuters) - Dechra Pharmaceuticals Plc ::Trading update.Trading in full year was strong and in line with management expectations.Reported group revenue for period increased by c.28% at constant exchange rate.European pharmaceuticals revenue growth was c.7% at cer.North America pharmaceuticals revenue growth was c.93% at cer.  Full Article

Kane Biotech says entered into license and distribution agreement with Dechra Veterinary Products
Monday, 6 Mar 2017 07:35am EST 

Kane Biotech Inc : Kane biotech inc- terms of agreement are confidential between parties and further financial details are not disclosed . Kane biotech inc - has entered into exclusive license and distribution agreement with dechra veterinary products llc, unit of dechra pharmaceuticals . Kane biotech- to receive upfront payment upon signing along with series of potential payments to combined maximum of usd $2.0 million .Kane biotech inc - will receive an ongoing royalty on net sales of its products by dechra in north america.  Full Article

Dechra Pharmaceuticals says half-year revenue up at 172.6 mln stg
Monday, 27 Feb 2017 02:43am EST 

Dechra Pharmaceuticals Plc : Half-Yearly financial report 2017 . Half-Yearly financial report 2017 for six months ended 31 december 2016 . Hy total group revenue of £172.6 million, a growth of 34.7 pct at constant exchange rate (cer) (55.9 pct at actual exchange rate (aer)). . Hy core (excluding acquisitions) european pharmaceuticals (eu pharmaceuticals) segment revenue growth of 5.9 pct at cer (20.0 pct at aer). . Hy underlying operating profit increased by 28.6 pct at cer (47.1 pct at aer). .Net cash inflow from underlying operating activities of £43.9 million with a cash conversion of 124.0 pct..  Full Article

Dechra Pharma expresses confidence about its FY expectations
Tuesday, 17 Jan 2017 02:00am EST 

Dechra Pharmaceuticals Plc : Trading update . Issues following unaudited trading update covering half year reporting period from 1 July to 31 December 2016 . Reported group revenue for period increased by approximately 34 pct at constant exchange rate (CER) (56 pct at actual exchange rate (AER)) . Core group revenue growth, excluding benefit from acquisitions, was 7 pct at CER (AER 22 pct); growth in core EU business was 6 pct at cer (AER 20 pct), and 10 pct (AER 31 pct) in North America . All acquisition integrations are progressing well with revenue contributions from Genera, Putney, Apex and Brovel being ahead of board's expectations. .We remain confident in our strategy, our future prospects and our expectations for full year performance.  Full Article

Nagatanien Holdings to take out $130 mln worth loan for full acquisition of Broomco (3554) Limited
Friday, 2 Dec 2016 01:21am EST 

Nagatanien Holdings Co Ltd <2899.T>: Says it will use $130 million to buy 100 percent stake in the United Kingdom-based holding firm Broomco (3554) Limited . Says it will take out $130 million worth loan for the acquisition .Says the co plans to sell 40 percent stake in Broomco (3554) Limited to Innovation Network Corporation of Japan after the acquisition.  Full Article

Dechra Pharmaceuticals full year revenue up 21.7 pct
Monday, 5 Sep 2016 02:00am EDT 

Dechra Pharmaceuticals Plc : Final dividend 12.91 penceper share . Fy revenue rose 21.7 percent to 247.6 million stg . Total dividend 18.46 penceper share . Preliminary results announcement . Fy revenue growth in our existing eu pharmaceuticals segment was 5.7pct (at cer) . Product development pipeline continues to deliver results: recently launched products osphos ® and zycortal ® gaining good market penetration. . Geographical expansion enhancing revenue growth with good performance in poland and canada and new start-up in austria. . Although we anticipate a degree of uncertainty following brexit, business is naturally hedged by its geographical spread and international sourcing . Any significant downturn in uk economy may impinge on growth rates; however, we do not anticipate any material effect on group. . Fy group underlying operating profit growth was 20.9pct at cer for 2016 . Including non-underlying items, group's reported fy profit after tax of £12.5 million decreased by 27.7pct at cer (35.9pct at aer) .We delivered fy underlying operating profit of £52.9 million, representing a growth of 20.9pct compared to previous year.  Full Article

Dechra Pharma poaches finance head from Consort Medical
Wednesday, 17 Aug 2016 02:30am EDT 

Dechra Pharmaceuticals Plc : Appointment of chief financial officer .Appointment of Richard Cotton as chief financial officer.  Full Article

BRIEF-Dechra Pharmaceuticals Says HY Revenue Up 11 Pct

* SAYS REPORTED GROUP REVENUE FOR SIX MONTHS ENDED 31 DECEMBER 2017 INCREASED BY 11.2% AT CONSTANT EXCHANGE RATE